Incyte is reported to be close to a potential acquisition deal for Star Therapeutics valued at up to $2 billion, according to coverage cited by Financial Times. The proposed transaction would bring the blood-disorder drug developer under Incyte’s umbrella as the company looks to supplement its pipeline and expand in areas beyond large Big Pharma players. The reporting frames the move as part of a broader trend in which mid-sized drug manufacturers seek growth by scaling up and adding new therapeutic candidates or platforms through deals. While details on deal structure and timing are not provided in the excerpts, the sources converge on the key points that Incyte is in advanced discussions and that the total consideration could reach as high as $2 billion. Further information typically would be expected around the specific assets included in the transaction and the conditions that could affect final valuation. No other confirmed terms or regulatory milestones are included in the provided text.